comprehensive -WSS

comprehensive

author：knowledge 2025-09-06 04:37:20 - browse：8346

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Group behind ProMed defends move to subscription

leisure time

focus

WSS

Software glitch causes Tandem insulin pump to shutdown, FDA warns

First recipient of genetically engineered pig kidney has died

When waiting feels immoral: Empathy in the emergency department

Elevance, private equity launch primary care company

It costs an awful lot of money to give away a kidney

Biotech startup Celsius cuts 75% of staff ahead of first trial start

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Duchenne breakthrough therapy leaves behind pioneering families

When waiting feels immoral: Empathy in the emergency department

Novavax promises a turnaround & Lilly roils the obesity market

Bird flu outbreak in cows is latest avian flu curveball

Cancer drug shortages should be causing more outrage

Elevance, private equity launch primary care company

Duchenne breakthrough therapy leaves behind pioneering families

Heart disease in astronauts blamed on cosmic radiation

Trump demands the U.S. pay no more for drugs than other countries … again

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

explore

The a glaring gap in research on serious mental illness and primary care

H5N1 bird flu: what we're starting to learn about infection in cows

It costs an awful lot of money to give away a kidney

Researchers on aging grapple with how to calculate biological age

Medicare slashes safety net hospital payments by nearly $1 billion

Late stage cancers on the rise after pandemic delayed screenings

hotspot

leisure time

focus

hotspot